Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  BTK inhibitor ACP-196
Find trials that include:  Any drugs shown
Results 1-13 of 13 for your search:
Start Over
Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-006, NCI-2015-01966, NCT02477696
Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-007, NCI-2015-02261, NCT02475681
ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-001, NCI-2014-00263, NCT02029443
ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-LY-001, NCI-2015-00533, NCT02328014
ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-004, NCI-2015-00489, NCT02213926
Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-007, NCI-2015-01131, NCT02448303
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-006, NCI-2015-01085, NCT02454179
Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-004, NCI-2015-01930, NCT02570711
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-208, NCI-2015-02121, NCT02537444
ACP-196, a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-002, NCI-2014-01462, NCT02112526
An Open-label, Phase 1b Study of ACP 196 Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-003, NCI-2014-02238, NCT02180711
ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-003, NCI-2014-02555, NCT02296918
Start Over